Summary of findings: insulin degludec vs insulin glargine
Serious adverse events (n/N)
Summary of findings: insulin degludec showed no clear difference in serious adverse events (n/N) compared with insulin glargine (low certainty).
1 finding from 1 review
- (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes onlyRR 0.92 [0.58, 1.46]3 studies · 970 participantsLow